(Date:11/6/2009)...Calif., Nov. 6 Intarcia Therapeuti...ITCA 650 (DUROS® continuous delivery of exena... at the Ninth Annual Diabetes Technology Meeting i...com.com/cgi-bin/prnh/20050301/SFTU126LOGO ) ,, ...a ITCA 650 Lowers Plasma Glucose, HbA1c and Reduce...
(Date:11/5/2009)...N, Colo., Nov. 5 The endangered bl...e western U.S. This rare carnivore feeds on prair...o plague and often entire population die-offs in t...(FWS) has implemented a ferret breeding program an... their formerly native habitat. Unfortunately, pl...
(Date:11/5/2009)...e Call on Thursday, November 5, 2009 at 4:30 p.m. ... 5 /PRNewswire-FirstCall/ - OncoGenex Pharmaceutic... OGXI ) today reported unaudited financial results...mber 30, 2009 and reviewed the Company,s highlight...ng consolidated results reflect the operations of ...
(Date:11/5/2009)...H, Texas, Nov. 5 Wound M...day that it has entered into a Letter of Intent to... Health Technologies, Inc. (OTC Bulletin Board: VH...000 in cash and debt, 4,000,000 shares of WNDM and...M on the Veriscrip technology being acquired from ...
Breaking Biology Technology:Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 2Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 3Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 4Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 5Colorado Companies Team Up With U.S. Fish & Wildlife Service to Protect Black-Footed Ferret 2OncoGenex Reports Third Quarter 2009 Financial Results 2OncoGenex Reports Third Quarter 2009 Financial Results 3OncoGenex Reports Third Quarter 2009 Financial Results 4OncoGenex Reports Third Quarter 2009 Financial Results 5OncoGenex Reports Third Quarter 2009 Financial Results 6OncoGenex Reports Third Quarter 2009 Financial Results 7OncoGenex Reports Third Quarter 2009 Financial Results 8OTCBB-WNDM Announces LOI to Acquire VHGI Assets for $10 Million Cash/Stock 2OTCBB-WNDM Announces LOI to Acquire VHGI Assets for $10 Million Cash/Stock 3...sive challenges and opportunities for micro and na...anufacturing of the fibres but in the control and ...workshop will focus on the many challenges of fibr...-of-the art surface chemical analysis, including S...damental effects of topography in SIMS and XPS, AF...
...Calif., May 14 VaxGen,Inc. (OTC Bulletin Board: V...guidance on its expected monthly cash expenditures...n on April 9, 2008. VaxGen expects that,its averag...kely to exceed,$1 million, made up of the followin...real estate and facility, estimated at 32% of m...
...dea Biosciences, Inc.,(Nasdaq: RDEA ) today annou...e Company,s lead mitogen-activated ERK kinase (MEK...W) 2008 in San Diego., The oral presentation det... 20, 2008 at 3:30 p.m. Pacific Time Abstract ...Inhibitor Ameliorates Murine Colitis Se...
Other Biology Technology:Micro and Nano Scale Characterization of Fibers 2Vaxgen Files 10-Q for First Quarter With SEC, Provides Future Burn Rate Guidance 2Vaxgen Files 10-Q for First Quarter With SEC, Provides Future Burn Rate Guidance 3Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at Digestive Disease Week 2008 2ScriptCap m7G Capping System from EPICENTRE Biotechnologies
EXTRACTI-GEL D from Pierce Biotechnology, Inc.
...vides high speed and excellent temperature uniform...adient Thermocycler can be run without any modific...ock for 48 or 96 wells. In addition, modules for 3...le. The High Precision Smart Lid provides automati...
Agencourt SPRPlate D - Disc Magnet Plate from Agencourt Bioscience
Biology Products: